Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan
Yin-Ching Chuang, Chia-Ming Chang, Sacchidanand Aradhya, Bheerappa Nagari, Vishwanath Pai, Nathalie Dartois, Sylvie Jouve, Angel Cooper
Received: September 4, 2009 Revised: May 4, 2010 Accepted: May 16, 2010
Chi-Mei Medical Center, 901 Chung-Hua Rd, Yung-Kang Dist., Tainan City 710, Taiwan.
E-mail address: firstname.lastname@example.org (Y.-C. Chuang).
Background and purpose:
To compare the monotherapy of tigecycline with vancomycin-aztreonam in hospitalized patients from India and Taiwan with complicated skin and skin structure infections (cSSSIs).
Safety and efficacy data were analyzed for Indian (n = 86) and Taiwanese (n = 41) patients hospitalized with cSSSIs who participated in two international Phase 3, randomized, double-blind studies.
Patients were treated for 5–14 days. Cure rates at the test-of-cure assessment (12–92 days post-therapy) were generally similar between tigecycline and vancomycin-aztreonam in the clinically evaluable populations (India, 83.3% vs. 75.8%; Taiwan, 78.6% vs. 90%) and in the clinical modified intent-to-treat populations (India, 78.6% vs. 66.7%; Taiwan, 73.3% vs. 75.0%). Nausea and vomiting occurred more frequently with tigecycline, but overall safety and tolerability were comparable between the two treatments.
Tigecycline monotherapy is a safe and effective therapy for cSSSIs in geographically distinct populations in Asia.
Complicated skin and skin structure infections, Efficacy, India, Taiwan, Tigecycline